作者
David I Rosenthal, Pamela Nurenberg, Carlos R Becerra, Eugene P Frenkel, David P Carbone, Bert L Lum, Richard Miller, Julie Engel, Stuart Young, Dale Miles, Markus F Renschler
发表日期
1999/4/1
期刊
Clinical cancer research
卷号
5
期号
4
页码范围
739-745
出版商
American Association for Cancer Research
简介
Gadolinium Texaphyrin (Gd-Tex) is a radiation sensitizer with a novel mechanism of action that sensitizes both oxic and hypoxic cells, localizes selectively in tumors, and is detectable by magnetic resonance imaging (MRI). This Phase I single-dose trial of Gd-Tex administered concurrently with radiation therapy was carried out to determine the maximally tolerated dose (MTD), dose-limiting toxicities, pharmacokinetics, and biolocalization of Gd-Tex as determined by MRI. Adults with incurable cancers of any histology requiring radiation therapy were eligible. A single i.v. dose of Gd-Tex was followed at least 2 h later by radiation therapy. The Gd-Tex dose was escalated in cohorts of 3 to 5 patients. Thirty-eight patients (median age, 58 years; range, 35–77 years) with incurable cancers of the lung (26), cervix (3), or other solid tumors (9) received a total of 41 single administrations of Gd-Tex. The Gd-Tex dose was …
引用总数
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024371084916111086356445656735222